コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 2 billion (28% of hospital charges or 79% of hospital cost).
2 rally inserted central catheters (PICC), and hospital cost.
3 Excessively prolonged hospitalization and hospital cost.
4 Hospital charges were used as a proxy for hospital cost.
5 ns have been shown to significantly increase hospital cost.
6 ty, complications, length of stay, and total hospital cost.
7 stay, development of C. difficile, or total hospital cost.
8 of Clostridium difficile colitis, and total hospital cost.
9 stay, ICU days, nonbeneficial treatments, or hospital costs.
10 nce of pulmonary complications and increased hospital costs.
11 rtality, prolonged length of stay, and total hospital costs.
12 seem to improve outcomes without increasing hospital costs.
13 alizations and approximately $242 million in hospital costs.
14 ts had longer hospitalizations and increased hospital costs.
15 associated with decreased length of stay and hospital costs.
16 cian costs were estimated as a percentage of hospital costs.
17 Length of stay and hospital costs.
18 sts were $27 billion representing 12% of all hospital costs.
19 associated with increased patient charges or hospital costs.
20 ements, length of ICU and hospital stay, and hospital costs.
21 aureus prolongs length of stay and increases hospital costs.
22 length of critical care or hospital stay or hospital costs.
23 rct size, hospital length of stay, and total hospital costs.
24 tay, increased early and late mortality, and hospital costs.
25 Our primary outcome was 90-day total hospital costs.
26 ICU and hospital lengths of stay, and total hospital costs.
27 p VAP incur > or = USD $10,019 in additional hospital costs.
28 imaging, and total imaging relative to total hospital costs.
29 se in LOS, and nearly 7500 dollars in excess hospital costs.
30 significantly higher intensive care unit and hospital costs.
31 ital and its effects on patient outcomes and hospital costs.
32 macy stewardship personnel time on the total hospital costs.
33 ociated with meaningful increases in LOS and hospital costs.
34 opic GBP were adequately offset by the lower hospital costs.
35 nditures were smaller than the reductions in hospital costs.
36 n scars but incurred a longer LOS and higher hospital costs.
37 ted with a 7.4% (7.1-7.6) increase in annual hospital costs.
38 terventions, allowing possible reductions of hospital costs.
39 ed morbidity, mortality, length of stay, and hospital costs.
40 lity of life-adjusted survival and increased hospital costs.
41 37.24; P < .001) were associated with higher hospital costs.
42 ated with increased hospital utilization and hospital costs.
43 hospital costs were strongly associated with hospital costs.
44 spitalization, length of stay in an ICU, and hospital costs.
45 dary outcomes included Medicare spending and hospital costs.
46 rate and is also associated with significant hospital costs.
47 , is associated with increased mortality and hospital costs.
48 for approximately 25% of non-implant-related hospital costs.
49 U length of stay, discharge disposition, and hospital costs.
50 .31 +/- 9.43 for OA; P < 0.001), and reduced hospital costs (12,125 +/- 14,430 for LA vs 17,594 +/- 2
51 4.1-5.5; p < .0001), and higher attributable hospital costs ($12,617; 95% confidence Interval, $10,75
52 < 0.001 and 28.0 vs 24.1 d; p < 0.001), and hospital costs ($150,569 vs $102,823; p < 0.001) were si
53 spital stay (2.06 +/- 1.06 days), and higher hospital costs [$18,579 (15,204-21,954) vs $14,063 (12,4
54 I, -0.46 to -0.16; P < 0.01) length-of-stay, hospital costs (-$2,559; 95% CI, -$4,508 to -$609; P = 0
55 outcomes from a recent randomized trial and hospital costs (2013 US$) from a university pancreatic d
56 stays (23.2 vs. 9.1 days, p < 0.001), higher hospital costs (21,144 dollars vs. 5,785 dollars, p < 0.
59 +/- 17.2 vs. 16.7 +/- 15.3 h, P = 0.36), and hospital costs ($4,242 +/- $3,871 vs. $4,364 +/- 1781, P
60 cal care medicine costs represented 13.4% of hospital costs, 4.1% of national health expenditures, an
62 (2) high turnover hospitalization, (3) total hospital cost, (4) transfer to the intensive care unit,
63 Median length of stay (17 vs. 6 days) and hospital costs ($40,903 vs. $13,434) also were higher wi
66 er and had significantly lower adjusted mean hospital costs ($6194; 95% confidence interval [CI], $57
67 rate (64 [50%] vs. 237 [34%]; p <.001), and hospital costs (70,568 dollars vs. 21,620 dollars, p <.0
68 in comparable but not significantly reduced hospital costs (7825 +/- 6,009 for LA vs 7841 +/- 13,147
69 , 1-15; p =.012) and a 61% increase in total hospital cost ($8,839; 95% CI, $ 1,674-$19,192; p =.013)
70 +/- 0.6 vs. 13.9 +/- 0.3), had higher median hospital costs ($80,500 vs. $29,604, p < .0001) and medi
72 21 [51%] vs. 301 [28%], p = .001), and total hospital costs (83,544 dollars vs. 23,803 dollars, p < .
73 day 4 was associated with a 43% increase in hospital costs, a 29% increase in physician service cost
74 iated pneumonia is associated with increased hospital costs, a greater number of days in the intensiv
79 ed utilizing patient data generated from the hospital cost accounting system and included additional
80 , between 1996 and 2002 were downloaded from hospital cost-accounting system; sample was restricted t
81 omplications, length of hospital stay (LOS), hospital cost, acute readmissions for reconstruction, an
82 atory Care was the third largest category of hospital costs after beds (27%) and pharmacy expenses (2
83 Older age was associated with lower total hospital costs after controlling for sex, intensive care
86 e estimated pound4.5 billion of total annual hospital costs among all women aged 55-79 years in Engla
88 alyses were employed to compare outcomes and hospital costs among patients who had alvimopan versus n
89 hospital discharge, and resource use (total hospital cost and discharge disposition among survivors)
90 were used to explore the association between hospital cost and in-hospital mortality, controlling for
91 n, multivariate linear regression models for hospital cost and length of stay were created to account
92 nger ICU and hospital LOS, with higher crude hospital cost and mortality rate compared with uninfecte
95 om 2001 through 2009 was performed using the Hospital Cost and Utilization Project State Inpatient Da
97 Participants were followed up and annual hospital costs and admission rates were estimated for Ap
98 ied differences in risk-adjusted incremental hospital costs and complications probabilities were comp
99 ing of the effects of excess weight on total hospital costs and costs for different health conditions
102 sessed differences in in-hospital mortality, hospital costs and length of stay between low- and high-
109 m $56.6 to $81.7 billion), the proportion of hospital costs and national health expenditures allocate
114 are might be an effective strategy to reduce hospital costs and the volume of patients in the ED.
116 intenance of equipment, and direct technical hospital costs) and benefit of care (based on difference
118 in-hospital mortality rate, length of stay, hospital cost, and complications after esophageal resect
119 sociated with shorter lengths of stay, lower hospital cost, and decreased frequency of postoperative
122 hospital within 90 days, hospital bed-days, hospital costs, and 6-month new disability (progression
123 drug therapies have a significant impact on hospital costs, and effective clinical informatics servi
126 Based on present value of future earnings, hospital costs, and lost income estimates due to illness
128 ios were most sensitive to variation in age, hospital costs, and probability of readmission, although
130 ntilation, ICU and hospital lengths of stay, hospital costs, and the percentage of patients requiring
131 nosis before initiating therapy, to decrease hospital costs, and to prevent inappropriate antimicrobi
133 genital cardiac surgery, mortality rates and hospital costs are significantly lower than when perform
134 axis over a wide range of valganciclovir and hospital costs, as well as variation in the incidence of
135 s and regulatory agencies should risk-adjust hospital cost assessments using clinical information tha
138 st catheterization failed, and the inpatient hospital costs associated with complications from the pr
142 a reduction in mortality, length of stay, or hospital cost attributable to the introduction of the eI
143 uctions in resource use, usually measured as hospital costs (average decrease, 13.4%) or average leng
146 was constructed to determine short-term "in-hospital" costs, based on outcome data derived from a pr
148 cessfully reduced the length of ICU stay and hospital costs, but were associated with a high rate of
151 ed mean length of stay by 0.4 days and other hospital costs by nearly $1,000 ($6,846 vs. $7,811, p =
154 ty (RR 0.71; 95% CI, 0.58-0.87), but similar hospital costs (CR 1.05; 95% CI, 0.95-1.16) compared to
155 idence (34.8% vs. 35.2%, p = 0.950) or total hospital costs (data as medians with 25%, 75% percentile
156 p personnel time to interventions, the total hospital costs decreased by $2,439 per bloodstream infec
159 ospital cost (incremental increase in median hospital cost estimated at $11,075; 95% confidence inter
160 (5.4 days vs 10.0 days; P < 0.001) and total hospital costs (euro2919 vs euro4262; P < 0.001) were si
161 mechanical ventilation, length of stay, and hospital costs, even at a time when patients are sicker.
162 EGDT reduced length of stay such that net hospital costs fell approximately 22.9% ($8,413-$8,978).
163 complications are associated with increased hospital costs following major surgery, but the mechanis
164 ociation of postoperative complications with hospital costs following total gastrectomy for gastric a
167 care costs based on inpatient and outpatient hospital costs for 28 DCD and 198 donation after brain d
169 the perspective of the hospital and included hospital costs for each admission plus the total annual
171 ess body weight is associated with increased hospital costs for middle-aged and older women in Englan
173 se job satisfaction, job turnover rates, and hospital costs for temporary agency nurses will improve
180 d] vs community acquired [3 d]), and median hospital costs (hospital acquired [$38,369] vs healthcar
183 tion on the rate of readmission or death and hospital costs in patients with heart failure (HF).
188 on was independently predictive of increased hospital cost (incremental increase in median hospital c
194 .3 versus 4.5 days; P<0.0001), with lower in-hospital cost (mean $18,640 versus $19,967 [median $14,4
195 yses were performed on key inputs including: hospital costs, mortality benefit, hazard ratio for hosp
196 ted therapy was associated with an increased hospital cost of $7,028 and an increase in both discount
197 nited States in 2003 at an annual aggregated hospital cost of > $16 billion, or nearly two thirds of
199 py in the Netherlands showed that mean total hospital cost of extracorporeal life support treatment i
202 However, few estimates have been made of the hospital costs of assessing and treating self-harm.
204 is large and detailed economic evaluation of hospital costs of extracorporeal life support therapy in
205 -adjusted incidence, outcome, and associated hospital costs of severe sepsis in United States childre
208 examining the effect of hospitalist care on hospital costs or on medical utilization and costs after
209 ed with prolonged hospitalization, increased hospital costs, patient dissatisfaction, morbidity, and
213 5+/-7 versus 3+/-2 days; P=0.0097) and total hospital costs per admission ($26,826+/-29,497 versus $1
214 pre-BIG group, 6.1 [4.8] days; P = .03), and hospital costs per patient ($4772 per patient; P = .03)
220 pic subgroups had significantly higher total hospital costs, ranging from &OV0556;501 (<75 years ASA
222 ality risk, longer hospital stay, and higher hospital costs relative to bacterial bloodstream infecti
223 trospective analysis was performed using the Hospital Cost Report Information System (Centers for Med
224 spital Association dataset, and (d) Medicare Hospital Cost Report Public Use files and wage index fil
228 ength of stay by 1.6 days (P = 0.002), and a hospital cost savings of $1492 per patient (P = 0.01).
232 her 30-day mortality, Medicare spending, and hospital costs than patients admitted to a general hospi
233 se who were adherent had significantly lower hospital costs than the other groups; pharmacy costs wer
234 h surgical complexity, is more predictive of hospital costs than the subsequent treatment of postoper
237 e over 2 years, and medical resource use and hospital costs through 12 months were used to project li
238 nd total hospital costs, derived using whole-hospital cost to charge ratios, were calculated for each
239 care reimbursement levels using the ratio of hospital costs to Medicare reimbursement and categorized
240 r using US EQ-5D scores) and accrued greater hospital costs (UK pound101 [SE pound37]; US $145 [SE $5
241 (6 days vs 9 days, P = 0.016), and lower in-hospital costs (US $16,717 vs US $24,014) were significa
244 hip/knee replacements was $26.0 billion, the hospital cost was $9.1 billion, and the amount of reimbu
248 ects of any and each complication on LOS and hospital cost were estimated in multivariable models, ad
255 ntly 21.7 days shorter (P = 0.0484) and mean hospital costs were $60,729 lower (P = 0.02) than in the
267 , quality of life, medical resource use, and hospital costs were collected during the trial and used
268 admission rate, length of hospital stay, and hospital costs were collected from the University Health
276 neurysms, discharge outcomes were better and hospital costs were lower after endovascular treatment t
277 an difference pound 19, 95% CI 11-27); total hospital costs were lower for those infants, but the dif
283 ICU and hospital length-of-stay, and ICU and hospital costs were measured during the 3 study periods.
293 ive complications, length of stay, and total hospital costs were strongly associated with hospital co
294 urgical complexity, and outcomes, along with hospital costs, were analyzed for a random sample of 587
295 d to determine the impact of care setting on hospital costs while controlling for patient demographic
297 were independently associated with increased hospital costs, with major bleeding, arrhythmia, and dea
299 ction, increase bed availability, and reduce hospital costs without increasing adverse patient outcom
300 ting data on the influence of laparoscopy on hospital costs, without separate analyses based on opera
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。